Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2026-02-20 @ 8:19 AM
Study NCT ID:
NCT01787669
Status:
COMPLETED
Last Update Posted:
2018-11-13
First Post:
2013-02-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Sponsor:
University of Sydney
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SwitchDMO
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |